Limits...
Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Clafshenkel WP, King TL, Kotlarczyk MP, Cline JM, Foster WG, Davis VL, Witt-Enderby PA - Evid Based Complement Alternat Med (2012)

Bottom Line: Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits.However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice.A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

ABSTRACT
Morinda citrifolia (noni) is reported to have many beneficial properties, including on immune, inflammatory, quality of life, and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the effects of Tahitian Noni Juice (TNJ) on mammary carcinogenesis were examined in MMTV-neu transgenic mice. Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits. However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form of cancer occurred with the mouse equivalent of a recommended dose for humans (<3 oz/day). A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modified reproductive responses are needed to characterize its potential as a CAM therapy for women with and without HER2(+) breast cancer.

No MeSH data available.


Related in: MedlinePlus

Example sections for the negative control (no primary antibody) and for immunostaining with anti-von Willebrand factor in MMTV-neu mammary tumors. (a) Staining was absent in a negative control section. The primary antibody was replaced with nonimmune serum (1 : 100) for negative control slides. (b) Immunohistochemistry resulted in isolated clusters of epithelial cells (arrow) in sections of mouse mammary tumors stained with anti-von Willebrand factor antibody (1 : 100). Sections were counterstained with Harris hematoxylin. Original magnification 200x.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3351229&req=5

fig4: Example sections for the negative control (no primary antibody) and for immunostaining with anti-von Willebrand factor in MMTV-neu mammary tumors. (a) Staining was absent in a negative control section. The primary antibody was replaced with nonimmune serum (1 : 100) for negative control slides. (b) Immunohistochemistry resulted in isolated clusters of epithelial cells (arrow) in sections of mouse mammary tumors stained with anti-von Willebrand factor antibody (1 : 100). Sections were counterstained with Harris hematoxylin. Original magnification 200x.

Mentions: The prevalence of necrosis in mammary tumor sections (Figure 3(a)) was determined by a board-certified veterinary pathologist (J.M.C.), with a nearly significant increase in central necrosis detected with TNJ treatment (P < 0.064, Fisher's exact test; Table 1). To determine if a potential cause of the necrosis could be due to poor vascularization of the tumors, blood vessels were quantified in tumor sections by immunostaining for von Willebrand factor (Figure 4). The average number of immunopositive blood vessels in the tumors did not vary significantly between groups (Table 1), although this may be attributed to a small sample size.


Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Clafshenkel WP, King TL, Kotlarczyk MP, Cline JM, Foster WG, Davis VL, Witt-Enderby PA - Evid Based Complement Alternat Med (2012)

Example sections for the negative control (no primary antibody) and for immunostaining with anti-von Willebrand factor in MMTV-neu mammary tumors. (a) Staining was absent in a negative control section. The primary antibody was replaced with nonimmune serum (1 : 100) for negative control slides. (b) Immunohistochemistry resulted in isolated clusters of epithelial cells (arrow) in sections of mouse mammary tumors stained with anti-von Willebrand factor antibody (1 : 100). Sections were counterstained with Harris hematoxylin. Original magnification 200x.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3351229&req=5

fig4: Example sections for the negative control (no primary antibody) and for immunostaining with anti-von Willebrand factor in MMTV-neu mammary tumors. (a) Staining was absent in a negative control section. The primary antibody was replaced with nonimmune serum (1 : 100) for negative control slides. (b) Immunohistochemistry resulted in isolated clusters of epithelial cells (arrow) in sections of mouse mammary tumors stained with anti-von Willebrand factor antibody (1 : 100). Sections were counterstained with Harris hematoxylin. Original magnification 200x.
Mentions: The prevalence of necrosis in mammary tumor sections (Figure 3(a)) was determined by a board-certified veterinary pathologist (J.M.C.), with a nearly significant increase in central necrosis detected with TNJ treatment (P < 0.064, Fisher's exact test; Table 1). To determine if a potential cause of the necrosis could be due to poor vascularization of the tumors, blood vessels were quantified in tumor sections by immunostaining for von Willebrand factor (Figure 4). The average number of immunopositive blood vessels in the tumors did not vary significantly between groups (Table 1), although this may be attributed to a small sample size.

Bottom Line: Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits.However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice.A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

ABSTRACT
Morinda citrifolia (noni) is reported to have many beneficial properties, including on immune, inflammatory, quality of life, and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the effects of Tahitian Noni Juice (TNJ) on mammary carcinogenesis were examined in MMTV-neu transgenic mice. Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits. However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form of cancer occurred with the mouse equivalent of a recommended dose for humans (<3 oz/day). A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modified reproductive responses are needed to characterize its potential as a CAM therapy for women with and without HER2(+) breast cancer.

No MeSH data available.


Related in: MedlinePlus